Methyldopa hypotension and ascending projections from midline serotonin (B3) cells in the medulla

Area of Science:

• Neuroscience
• Cardiovascular Physiology
• Pharmacology

Background:

• The B3 serotonin cell group in the ventral medulla plays a role in cardiovascular regulation.
• Methyldopa is an antihypertensive drug whose precise central mechanisms are not fully elucidated.
• Spontaneously hypertensive rats, stroke-prone strain (SHRSP) serve as a model for studying hypertension and its complications.

Purpose of the Study:

• To investigate the role of the midline B3 serotonin cell group in the hypotensive effect of methyldopa.
• To determine the projection pathways involved in methyldopa-induced hypotension originating from the B3 serotonin cells.

Main Methods:

• Micro-injection of methyldopa into the B3 serotonin cell area of SHRSP.
• Lesioning of serotonin pathways using intracerebroventricular, intraspinal, and median forebrain bundle injections of 5,7-dihydroxytryptamine (5,7-DHT).
• Monitoring of blood pressure changes following drug administration and neurotoxin treatment.

Main Results:

• Micro-injection of methyldopa into the B3 serotonin cell group induced a significant fall in blood pressure (30-40 mmHg).
• Intracerebroventricular 5,7-DHT abolished the methyldopa-induced hypotension, indicating a central serotonergic mechanism.
• Lesions of descending spinal serotonergic pathways or ascending pathways in the median forebrain bundle did not affect the hypotensive response.

Conclusions:

• The midline B3 serotonin cells in the medulla are crucial for the hypotensive action of methyldopa.
• The mechanism involves a projection pathway restricted to the caudal brainstem, likely within the medulla itself.
• These findings elucidate a specific central pathway involved in methyldopa's antihypertensive effects.